OncoMed presents data for Anti-DLL4/VEGF
OncoMed Pharmaceuticals presented initial first-in-human data from its ongoing Phase 1 clinical trials of anti-DLL4/VEGF bispecific and anti-RSPO3 antibodies in two posters at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium being held in Munich, Germany. "In these first-in-human Phase 1 trials of our anti-DLL4/VEGF bispecific and anti-RSPO3 antibodies we have accomplished the primary goal of defining the safety profiles and establishing the single-agent doses for these agents. We have also observed initial evidence of anti-tumor activity in patients treated to date," said Jakob Dupont, M.D., Chief Medical Officer of OncoMed. "Dual blockade of DLL4 and VEGF has shown synergies preclinically, and in the clinic we are seeing evidence of single-agent activity with partial responses in ovarian and uterine cancers and stable disease in about one-third of the Phase 1 patients treated. We look forward to completing these trials and, in the near future, initiating Phase 1b studies with the anti-DLL4/VEGF bispecific in combination with standard of care in ovarian and colorectal cancers."